Psychedelic-Assisted Therapy and the Question of Legitimacy

The doors of perception are open. Not just a crack. But wide open.

In early 2026, positive late-stage data for psilocybin-assisted therapy and renewed progress around compounds like DMT signaled that regulatory approval could come sooner than we think. At the same time, public familiarity with these substances continues to expand. Decriminalization efforts. Media coverage. Veteran advocacy. Silicon Valley microdosing culture. And decades of underground therapeutic use that happened whether the law approved or not.

What makes this category unusual is that scientific validation and cultural meaning are developing in parallel. That almost never happens. In most drug categories, legitimacy flows in a predictable direction: from regulator to physician to patient, and eventually into broader culture. Clinical data establishes authority, adoption follows.

Psychedelics flipped the order.

For decades, these substances accumulated cultural legitimacy outside of formal medicine, through spiritual traditions, countercultural exploration, informal therapeutic networks, and patient-led experimentation. By the time clinical trials arrived, many patients and some clinicians already had opinions, expectations, and lived experience. The narrative around psychedelics wasn't shaped by a CSR. It was shaped in part by Michael Pollan’s book, “How to Change Your Mind.” By a veteran's testimony. By someone's cousin who came back from a retreat different than when they left.

That inversion matters. Clinical approval confers regulatory legitimacy. It establishes safety and efficacy. But in this category, cultural legitimacy—the social permission to integrate these therapies into practice and into life—will shape adoption just as powerfully. A treatment isn't fully real to the public until and unless it feels real.

Psychedelic-assisted therapy is not a context-independent intervention. Expectation influences experience. Experience mediates outcome. And expectations are formed long before a patient enters a clinic. They're shaped by history, by media, by community narratives, by prior exposure. The "set and setting" of the treatment room are, in a very real way, influenced by the "set and setting" of the broader culture.

This means legitimacy in this space isn't granted solely by data. It's negotiated. A complex interplay between scientific evidence and preexisting cultural adoption.

If psychedelic commercialization proceeds as though FDA approval is the start, it risks overlooking that negotiation. The same institutions that once criminalized these substances are now positioned to steward them. For many stakeholders—trauma therapists who have witnessed underground breakthroughs, indigenous groups with centuries of sacramental use, veterans who sought treatment outside the system—this shift will require more than evidence. It will require thoughtful acknowledgment of history.

That doesn't mean romanticizing illegal use or diluting clinical rigor. Regulatory discipline is essential. But rigor and historical awareness aren't in tension. Ignoring the past doesn't strengthen institutional authority, it narrows it. It creates a blind spot where trust can falter.

As additional molecules advance and therapeutic models diversify, differentiation will follow. In that environment, adoption won't depend solely on efficacy data. It will depend on the answers to three questions: Do physicians feel comfortable and supported integrating these therapies into practice? Do patients perceive the clinical pathway as credible and aligned with their understanding of the experience? And does the broader public view medical stewardship of these substances as legitimate?

Psychedelic medicine is advancing on two fronts, scientific and cultural, and neither is likely to slow. How it ultimately integrates into mainstream medicine will depend on how thoughtfully we reconcile those trajectories. Acceptance won't come from branding psychedelic-assisted therapy as something new, but by acknowledging where it has been, thereby granting it legitimacy in the future.